BlackRock Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

BlackRock Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.43M	Buy	43,233 +7,124	+20%	+$517K	﹤0.01%	1833
2016 Q3	$2.53M	Buy	36,109 +3,434	+11%	+$190K	﹤0.01%	1965
2016 Q2	$1.27M	Buy	32,675 +3,548	+12%	+$148K	﹤0.01%	2457
2016 Q1	$1.18M	Buy	29,127 +299	+1%	+$19K	﹤0.01%	2373
2015 Q4	$2.56M	Buy	28,828 +12	+0%	+$947	﹤0.01%	1903
2015 Q3	$2.13M	Sell	28,816 -464	-2%	-$38.6K	﹤0.01%	2036
2015 Q2	$2.37M	Buy	29,280 +28,669	+4,692%	+$1.87M	﹤0.01%	2096
2015 Q1	$26K	Buy	611 +10	+2%	+$284	﹤0.01%	3390
2014 Q4	$9K	Hold	601	–	–	﹤0.01%	3720
2014 Q3	$8K	Hold	601	–	–	﹤0.01%	3761
2014 Q2	$9K	Sell	601 -8,038	-93%	-$91.7K	﹤0.01%	3677
2014 Q1	$110K	Buy	+8,639	New	+$117K	﹤0.01%	3292

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

BlackRock Investment Management's EGRX Position: Q4 2016 in Review

BlackRock Investment Management increased its Eagle Pharmaceuticals, Inc. (EGRX) stake by 20% in Q4 2016, buying an estimated $517K and bringing the position to 43,233 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

BlackRock Investment Management first reported a position in EGRX in Q1 2014 and has held it in 12 quarters since. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

BlackRock Investment Management held 43,233 shares of Eagle Pharmaceuticals, Inc. worth $3.43M as of Q4 2016.
BlackRock Investment Management bought 7,124 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $517K.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1833 holding.
BlackRock Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.